Drug-eluting balloons (DEBs) have emerged as a new application in percutaneous coronary intervention. DEBs have proven successful in the treatment of in-stent restenosis, but their role in de novo lesions is less clear. This paper provides a review of the current studies where DEBs have been used in coronary de novo lesions, either as part of a DEB-only strategy or in combination with another device, mainly a bare metal stent (BMS). By searching Pubmed and Embase we were able to identify 52 relevant studies, differing in design, intervention, and clinical setting, including patients with small vessel disease, bifurcation lesions, complex long lesions, acute myocardial infarction, diabetes mellitus, and elderly. In 23 studies, a DEB was combined with a BMS, 25 studies used a DEB-only strategy with only provisional BMS implantation, and four studies combined a DEB with a drug-eluting stent (DES). In the vast majority of studies, DEB in combination with BMS does not seem to improve clinical or angiographic outcome compared with DES, whereas a DEB-only strategy seems promising, especially when predilatation and geographical mismatch are taken into account. A lower risk of recurrent thrombosis with DEB compared with DES is not evident from the current studies. In conclusion, the main indication for DEB seems to be small vessel disease, especially in clinical scenarios in which a contraindication to dual antiplatelet therapy exists. The main approach should be a DEB-only strategy with only provisional bailout stenting, which has shown interesting results in different clinical scenarios.
DEB-only strategy with only provisional BMS implantation, and four studies combined a DEB with a drug-eluting stent (DES). In the vast majority of studies, DEB in combination with BMS does not seem to improve clinical or angiographic outcome compared with DES, whereas a DEB-only strategy seems promising, especially when predilatation and geographical mismatch are taken into account. A lower risk of recurrent thrombosis with DEB compared with DES is not evident from the current studies. In conclusion, the main indication for DEB seems to be small vessel disease, especially in clinical scenarios in which a contraindication to dual antiplatelet therapy exists. The main approach should be a DEB-only strategy with only provisional bailout stenting, which has shown interesting results in different clinical scenarios.
In general, larger randomized controlled studies with prolonged follow-up comparing DEB with However, restenosis from neointimal hyperplasia in the stented area, known as in-stent restenosis, remained a complication of BMS [3] . By combining the mechanical balloon dilatation of the vessel with local delivery of antiproliferative medicine, introduction of the drug-eluting stent (DES) reduced the incidence of in-stent restenosis [4, 5] . However, DESs imply other limitations, including increased bleeding risks associated with the need for prolonged dual antiplatelet therapy (DAPT) and the risk of late and very late stent thrombosis (ST) [6] [7] [8] [9] .
Drug-eluting balloons (DEBs) have been developed in recent years to overcome some of these limitations. DEBs are semicompliant angioplasty balloons covered with an antiproliferative drug that is rapidly released upon contact with the vessel wall. Thus, mechanical expansion of the vessel is combined with release of an antiproliferative drug without leaving a foreign body. Expected potential benefits are no ST by avoiding a foreign body and less bleeding risk due to a shorter need for DAPT [10] .
There is an established indication for the use of DEBs in the treatment of in-stent restenosis following implementation of a BMS or a DES [11] , but the role of DEBs in the treatment of de novo lesions is less clear. The purpose of this review is to present the existing literature in which a DEB has been used alone or in combination with a stent in the treatment of coronary de novo lesions, in order to outline the potential indications, benefits, and limitations of this treatment strategy.
Pubmed, Embase, and reference lists were searched for literature up to mid April 2016, and 52 relevant studies were identified, of which three were follow-up studies and six were substudies from other trials. The treatment strategy in question is rather new, but has undergone extensive investigation within recent years, and this review provides new data compared with a previous review from 2012 [12] . This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.
DRUG-ELUTING BALLOONS
Paclitaxel is at present the only drug used in DEBs for human coronary interventions. It is a lipophilic drug that readily crosses the cell membrane [13] . After cellular uptake it binds to microtubules, thereby inhibiting cell division and migration and hence proliferation of the cells [14] . Most DEBs are coated with 3 lg/mm 2 paclitaxel. Usually, 60 s is used for balloon inflation, allowing a homogenous transfer of 8-18% of the drug to the treated vessel wall [15] .
However, the development of DEB is complex and other factors than the active drug itself contribute to the effect of DEB. The coating of the balloon is important, as the coating should be physically able to maintain the drug on the balloon during transit to the lesion, thereby reducing wash off, while at the site of dilatation it should ensure a rapid and homogenous drug transfer to the vessel wall [16] . The coating differs with the contrast agent iopromide, the film-forming agent shellac, the amphiphilic butyryl trihexyl citrate, and urea being the most widely used. DEBs with other coatings are developed, but preclinical data are limited [17] . At present, eight different CE-approved DEBs are available and seemingly no class effect exists among them [11, 14, 18] . have yet to be investigated in humans [19, 20] .
Drug-Eluting Balloon in Combination with a Bare Metal Stent
The rationale for combining the DEB with a BMS is the rapid release of the antiproliferative drug to the surface of the treated segment, while preventing acute elastic recoil by implanting a BMS. As no DES is implanted, a shorter period of DAPT is needed, thereby reducing bleeding risk. Catheter based system with a distal an proximal occlusive segment, allowing for delivery of liquid drug at the central segment system with a distal an proximal occlusive segment, allowing for delivery of liquid drug at the central segment *** Studies using more than one type of DEB *** Studies using more than one type of DEB Clinical studies where a DEB was used in combination with a BMS are summarized in Table 1 .
Several studies have showed that BMS in combination with a DEB is superior to BMS alone [21] [22] [23] . Similar results were reported with DEB in combination with an EPC stent (''endothelial progenitor cell capturing stent''). The EPC stent is covered with human CD34
antibodies that capture circulating endothelial cells and thus provides rapid endothelialization.
Therefore, it cannot be considered a true BMS.
However, the PERfECT stent study [24, 25] showed that DEB in combination with an EPC stent was better than EPC stent alone; however, these findings were not supported by the PEGASUS study [26] . However, when DEB ? BMS are compared to DES, at best similar results have been reported [27] , but most studies have found the combination of DEB ? BMS inferior to DES. Thus, by using optical coherence tomography the OCTOPUS trial found that DEB ? BMS was associated with more pronounced neointimal proliferation than DES [28, 29] , while the IVUS study used intravascular ultrasound to show more pronounced neointimal hyperplasia in the DEB ? BMS group leading to more revascularizations than in the DES group [30] . However, the sequence seems to be of no clinical relevance, as several papers report similar clinical and angiographic results [23, 32, 33] . In the INDICOR study, angiographic analysis showed that most of the late lumen loss (LLL) happened at the stent edges, thus highlighting the potential pitfall of geographical mismatch [33] . The results are interesting because they open up for the opportunity of using BMS as a bailout strategy following a suboptimal result after DEB treatment [32] .
In summary, the studies presented above consist of mixed populations of patients with ischemic heart disease requiring PCI at a vessel with a reference diameter of 2-3 mm. While DEB in combination with a BMS performed better than a BMS-only strategy, the combination does not seem superior to DES in the treatment of such lesions. Furthermore, most studies compared the DEB with a paclitaxel DES, which might be misleading as sirolimus DES is considered to perform better than paclitaxel DEB [7, 34] . The sequence of DEB and BMS implantation does not seem to influence outcome as long as geographic mismatch is taken into consideration.
Drug-Eluting Balloon Alone
Several studies have focused on the use of a drug-eluting balloon alone (''DEB-only'') strategy in de novo lesions. This might be accompanied by implantation of a stent only in the case of acute elastic recoil or dissection, [35] . The absolute LLL is similar and independent of vessel diameter; and since small vessels have less room to accommodate neointimal tissue growth, restenosis of small vessels has remained a challenge even in the DES era [36] . Hence, it would be promising to totally avoid a stent implantation in such lesions. Studies using a DEB-only strategy in specific clinical scenarios other than small vessel disease are presented later.
The first study using a DEB-only strategy in de novo lesions was the PEPCAD I (Paclitaxel-Eluting PTCA-Balloon Catheter to
Treat Small Vessel Coronary Artery Disease) study [37] . A SeQuent Please DEB was used for dilatation, and the proportion of patients requiring additional BMS deployment was 27%. An intention-to-treat analysis showed MACE at 15.3% after 12 months. However, a per-protocol analysis indicated significantly different outcomes both clinically and angiographically in favor of the DEB-only strategy, with TLR of 5% in the DEB-only group and 28% in the DEB ? BMS group. This difference was likely explained by geographical mismatch, i.e., the BMS was partly deployed LLL late lumen loss-reflects the loss of lumen in the treated segment usually measured by subtracting the lumen diameter at follow-up from the lumen diameter just after the PCI procedure; MACE major adverse cardiac event-not consistently defined among the different studies, but most frequently including the combination of either death, myocardial infarct, target lesion revascularization, or target vessel revascularization; TLR target lesion revascularization-revascularization within the treated/stented area, usually including 5 mm of the proximal and distal segment adjacent to the treated/stented area In-balloon LLL, mm: 0.38 (7.5) 19% among the group without restenosis, but this could also be explained by the need for implantation of a BMS in more complex lesions. After a 3-year follow-up period, no additional major coronary events were observed in either group, suggesting that after the first 6 months, lesions are relatively stable [38] .
The SeQuent Please World Wide Registry was a large multicenter observational study assessing the safety and efficacy of the SeQuent Please DEB [39] . Across 75 centers, 2095 patients were included. In the subset of 572 patients with de novo stenosis, 491 patients were treated with DEB alone and 101 patients with DEB ? BMS (either planned or as part of bailout stenting). Low and comparable rates of TLR and MACE were reported in both groups, markedly lower than observed in previous studies.
Other smaller real-world registries have been performed assessing the SeQuent Please DEB using an all-comer inclusion strategy. In a multicenter registry of 156 patients treated with SeQuent Please DEB, 74 patients had treatment of de novo lesions [40] . A very low bailout frequency was reported, but clinical outcome was worse than in other registries and clinical trials. The authors speculated that this was due to a high-risk population [40] . A long-term follow-up registry was performed by Benezet et al., showing persistently low MACE and TLR rates after 36 months and no occurrence of vessel/stent thrombosis [41] .
Twenty-five percent received bailout BMS implantation which was not associated with a less favorable outcome (MACE 7.1% with additional BMS and 9.5% without BMS) [41] . The prospective Leipzig Registry evaluated the clinical outcome in 484 patients treated with a SeQuent Please DEB [42] . De novo vessel disease was seen in 76 patients (15.7%). In de novo lesions, no TLR was seen after 27 months. MACE was defined differently than in other studies and was thus difficult to compare [42] . Being the second largest real world registry, the SeQuent Please Small Vessel ''PCB Only'' Registry was a prospective multicenter study assessing the safety and efficacy of the SeQuent Please DEB in 447 patients [35] . A low bailout proportion was reported, as were low TLR and MACE rates, and additional stenting was only associated with marginally higher TLR rates (3.6% in the DEB-only vs. 4% in the DEB ? BMS group). [35] .
From the SeQuent Please Small Vessel ''PCB Only'' Registry, three substudies have been reported focusing on the DEB-only strategy for elderly patients (C75 years) [43] , patients with acute coronary syndrome [44] , and Asian vs.
Western patients [45] . These studies are presented in Table 3 MB main branch, SB side branch. For other abbreviations, see Table 1 enlargement happens in areas with high plaque burden [52] .
Shin et al. used a fractional flow reserve-guided approach to treat with either DEB or DES [54] . Following successful POBA treatment of a de novo lesion, the fractional flow reserve was measured and if favorable ([0.85) a DEB was applied, otherwise a DES was implanted. Sixty-six patients were included, 44 received a DEB and 22 a DES. No clinical events were reported after 12 months.
Angiographic follow-up after 9 months showed a sustained luminal gain in the DEB group, while lumen decreased in the DES group.
However, owing to larger acute luminal gain in the DES group following implantation, the net gain was still better in the DES group after 9 months. This reflects the problem of using LLL as an outcome measure when comparing a stent and a balloon, which will be discussed later. Furthermore, by design and use of fractional flow reserve to guide the treatment arm, DES implantation is most likely associated with more complex lesions, thereby complicating the comparison between groups. The study focused on rather large vessels with a reference diameter between 2.5 and 3.5 mm [54] . To gain insight into possible explanations for the observed positive remodelling, Ann et al.
performed a serial IVUS and fractional flow reserve study [55] . Twenty-seven patients were treated with a SeQuent Please DEB, and after 9 months the luminal gain persisted with a low LLL of 0.02. Intravascular ultrasound virtual histology analysis showed that plaque composition was unchanged but that the amount of atheroma volume decreased significantly, and that mean lumen area increased after 9 months. Four thin-cap fibroartheromas converted to thick-cap atheromas, suggesting that plaque stabilization may be promoted with DEBs [55] .
In summary, a DEB-only strategy proves efficient with results comparable to DES in a mixed clinical patient population with lesions in coronary vessels less than 2.5 mm. Only two randomized controlled trials comparing DEB against DES exist, which report on very heterogeneous outcomes, and the majority of studies are real-world observational registries. Bailout rate ranges from 3% to 36% and bailout seems to result in a worse outcome. Careful attention to avoid geographical mismatch as well as performing thorough predilatation before DEB treatment trends toward a better outcome.
Drug-Eluting Balloons in Specific Clinical Scenarios
In the following, studies of DEBs used in more specific clinical scenarios are presented. These studies are summarized in Table 3 .
Drug-Eluting Balloons in Bifurcation Lesions
Bifurcation lesions account for 15-20% of all lesions treated by PCI [56] . It offers a challenge for clinicians, and despite the use of DESs, treating bifurcations remains hampered by technical difficulties and suboptimal long-term results, especially with regard to the side branch (SB) [57] . Currently the preferred approach is stenting of the main branch (MB) with a DES and only provisional stenting of the SB [58] .
The Drug Eluting Balloon in BIfurcation UTrect (DEBIUT) registry was the first registry to report on outcomes following use of DEBs in bifurcation lesions [59] . A small 20-patient registry was set up to explore the efficacy and The DEBIUT randomized trial sought to expand on the results from the DEBIUT registry [59] , and investigated the use of predilatation with a DIOR-I DEB in the MB and SB followed by a BMS in the MB vs. BMS treatment of the MB vs.
Taxus DES treatment of the MB [62] . In all cases, predilatation with a regular balloon was performed before intervention in both MB and SB. DIOR-I DEB failed to show superiority in angiographic outcomes compared to BMS, showed clearly worse outcome as compared to DES, and thereby was unable to confirm the promising results from the observational DEBUIT registry [59] . with the SeQuent Please DEB followed by BMS implantation in the MB versus standard predilatation with plain balloons followed by XIENCE V DES in the MB [64] . Significantly more TLRs were observed in the DEB-treated group, mainly as a result of higher restenosis of the MB. The primary endpoint of LLL and secondary endpoint of MACE trended in favor of the DES group without reaching statistical significance. Overall, the authors concluded that there was no advantage of using DEB in the SB on the basis of current available data, and that XIENCE V DES in MB was at present a better strategy than BMS ? DEB in MB.
The BIOLUX-I study was the first study to combine an everolimus DES with a paclitaxel DEB in the treatment of bifurcation lesions [65] .
Following predilatation of MB, the SB was treated with a Pantera Lux DEB, and subsequently, a Xience Prime/Xience V DES was implanted in the MB. The rationale was to maintain the simplicity of provisional stenting with the advantage of reducing restenosis of the SB. The primary endpoint showed a low LLL of 0.10 mm at 9 months. A core lab analysis showed that only 11 of the 35 lesions were ''true'' bifurcation lesions. However, low LLL persisted when this group was assessed separately. Clinical complication rates were low, and the authors concluded that the combination of an everolimus DES and paclitaxel DEB is a safe approach.
PEPCAD-BIF expanded on the initial result by Schulz et al. [63] , being the second study using a DEB-only strategy in bifurcation lesions [58] . The lack of carina shift and the maintenance of natural flow distribution were among the potential benefits. Following successful predilatation of both MB and SB, 64 patients were randomly assigned to either SeQuent Please DEB treatment of MB and SB or POBA. Only five lesions required bailout stenting, all in the POBA group. The primary endpoint of in-lesion LLL was significantly lower in the DEB arm, and also low TLR rates were reported.
Drug-Eluting Balloons in Chronic Total Occlusion or Diffuse Long Lesions
Stent length is an independent predictor of in-stent restenosis and thrombosis [66] . Long, complex, and small vessel lesions, which are often hampered by several underlying comorbidities, create a challenge for the clinician.
Paclitaxel-Coated Balloon With Bare-Metal
Stenting in Patients With Chronic Total
Occlusions in Native Coronary Arteries (PEPCAD CTO) was the first study to investigate the combination of DEB and BMS in the treatment of complex chronic total occlusions [67] . The risks of restenosis and repeat revascularization after recanalization of chronic total occlusion are higher compared with de novo lesions. After successful recanalization of a chronic total occlusion in 48 patients, the native vessel segment was covered with BMS and finally treated with one or more DEBs. The group was compared with a historical comparable group treated with a Taxus DES. The BMS ? DEB combination was associated with similar clinical results and a non-significantly higher in-stent LLL compared to the matched Taxus DES group.
In a pilot study, Basavarajaiah et al. adopted the same approach of a combined DEB ? stent treatment of long diffuse lesions, but instead of BMS they used ''limus'' DES, assuming that a synergistic effect might be achieved with dual drug elution [68] . The intended strategy was to use DEB alone following predilatation, and in cases of a suboptimal result to implant a DES.
Forty-six patients with lesions deemed high risk for restenosis, with 97% of lesions measuring more than 30 mm, had one or more DES implanted following DEB treatment. In 20 patients the treated lesion was a de novo lesion (the rest being in-stent restenosis) and after 13 months a low MACE rate was reported in the de novo subgroup. There was one case of possible ST. It was not reported whether the thrombosis was in a de novo or an in-stent restenosis [68] . The same authors continued exploring a similar scenario where 63 patients with long diffuse lesions were treated with IN.PACT Falcon DEB or Pantera Lux DEB alone or in a planned combination with a DES, a ''hybrid'' approach [69] . By adopting this hybrid approach, the authors reported that overall stent length in long lesions may be reduced, thereby improving outcome. A matched cohort of 93 patients treated with DES alone in the same period was used for comparison. The average treated lesion length was similar between DEB ± DES and DES alone, but the total stented length differed significantly (29 vs.
mm). A 2-year follow-up revealed similar
rates of MACE and TLR [69] . The same author group presented another retrospective registry study of patients treated with the IN.PACT Falcon DEB [70] . The majority of lesions were diffuse (80% of lesions exceeding 20 mm) and located in small vessels (70% of vessels smaller than 2.5 mm). In 79 patients with de novo lesions, 22% required bailout where a DES was implanted. A MACE rate of 16.5% was reported after 15 months and, given the complexity of the lesions, the authors found this rate acceptable. No ST occurred [70] . Thrombus aspiration was performed in 56% and predilatation in 100% of patients before DEB treatment, which yielded a low 4% bailout rate. A 1-month follow-up revealed four deaths, but all unrelated to the infarct-related artery, yielding zero TLR.
Drug-Eluting Balloons in
The PAPPA (Safety and feasibility of a PAclitaxel-eluting balloon angioplasty Primary Percutaneous coronary intervention in Amsterdam) study included 100 patients presenting with STEMI and investigated a DEB-only strategy with the Pantera Lux DEB [71] . Thrombus aspiration was recommended and predilatation was mandatory, but bailout was 40%, markedly higher than in comparable studies. Despite the high bailout rate, good clinical outcomes were observed after 1 year. The high bailout proportion due to an excess rate of dissections is thought partly to be due to predilatation with a slightly oversized balloon.
One early ST occurring 1 h after PCI was observed.
As a substudy of the previous presented [44] .
Drug-Eluting Balloons in Patients with Diabetes
Percutaneous coronary intervention in patients with diabetes is associated with more morbidity and mortality than in other populations, and a high risk of restenosis around 30% after 
Drug-Eluting Balloons in Elderly Patients
As part of a substudy from the SeQuent Please Small Vessel ''PCB Only'' Registry [35] , Sinaga et al. were the first to investigate the use of DEBs in elderly patients [43] . In spite of an excess of comorbidities in the elderly (hypertension, renal impairment, atrial fibrillation, previous PCI) and more calcified lesions than in the younger age group, similar bailout rate (7.3%, age \75; 6.7%, age C75) and clinical outcome were observed in the two groups.
The authors noticed that the results are comparable with the everolimus-eluting stent from the SPIRIT Small Vessel trial that reported a clinically indicated TLR of 5.1% after 1 year [78] .
The recommendation for DAPT treatment was 1 month, and most of the patients received DAPT for this period with a small proportion exceeding it [43] . As older people in general are more at risk of complications with prolonged DAPT treatment, this study showed a low 6.1% MACE after 9 months despite the shortened DAPT duration, highlighting the tempting aspects of DEB treatment and thereby avoidance of prolonged DAPT treatment in the elderly patients.
In short, while the planned combination of DEB ? BMS does not seem promising, especially in acute myocardial infarction, a DEB-only approach seems interesting in a broad range of different clinical scenarios. It has been suggested that the disappointing outcome in the scenario of acute myocardial infarction is explained by the different drug uptake in the acute ruptured plaque with high thrombus burden or a hampering effect by the presence of a BMS [12] . In bifurcation lesions, conflicting results were reported, with DES treatment of MB associated with a favorable outcome compared to DEB ? BMS, whereas the DEB-only strategy in bifurcation indicated potentially promising results that warrant further investigation [58, 63] . DEB in patients with diabetes, diffuse lesions, and elderly also reveals interesting results. Overall, the limited data makes it difficult to draw any firm conclusions about the use of DEB in these specific patient groups.
STENT THROMBOSIS AND DUAL ANTIPLATELET THERAPY
Data on the duration of DAPT treatment, early or late stent thrombosis, geographical mismatch, and duration of follow-up in the studies are found in Table S1 [37, 46, 47, 49] ; however, several prospective registries using SeQuent Please DEB did not find a difference between DEB treatment with or without BMS implantation [35, 39, 41] . Geographical mismatch between the DEB-treated area and BMS implantation seems partly to account for the observed differences, where especially the stent edges are sites of restenosis, and thus geographical mismatch should be avoided, and a BMS only implanted as a part of a bailout strategy [21, 24, 28, 37, 49] . The sequence of DEB treatment, before or after BMS implantation, was not found to significantly alter the outcome [23, 32, 33] . When BMS is implanted prior to DEB treatment a natural reference point for DEB dilatation exists (i.e., the BMS); to avoid geographical mismatch, extra caution should be taken when DEB dilatation precedes BMS implantation because the reference point for BMS implantation might be missing [33] . Predilatation of the target lesion is thought to create microdissections in the vessel wall, which in turn facilitates the uptake of drug and is therefore generally recommended prior to DEB implantation [50] . Predilatation in the PICCOLETO study was significantly higher in the DES arm, and might also have favored DES treatment in this study.
Most studies report on data from treatments performed on relatively small vessels with a reference diameter ranging from 2.48 to 3.30 mm in the planned DEB ? BMS strategy and 1.95-2.80 mm in the DEB-only strategy, and with a follow-up of maximum 12 months except for five studies with at least 2 years of follow-up. As a potential benefit of using DEB was to avoid the late ST risk associated with DES implantation, the follow-up periods were generally too short to fully address this question. Furthermore, none of the studies included ST as a primary endpoint. Table S1 in the appendix illustrates that only the study by _ Zurakowski et al. [27] and PEPCAD I [37] [38, 77] , there is no current consensus about duration of DAPT, and other studies recommend 12 months of DAPT in case of BMS implantation [10, 27, 33] .
Most of the studies compared the paclitaxel DEB to a paclitaxel DES in order to compare treatment devices using the same drug. This might be misleading as the sirolimus-eluting DES was shown to perform better than paclitaxel-eluting DES [7, 34] . Furthermore, newer-generation limus DES (everolimus and zotarolimus) perform even better than sirolimus DES [79] . Thus, by using the best DES on the market, even better DES results would be expected, and the potential benefit of treatment with a DEB might diminish. While different drugs exist for DES, paclitaxel for now seems the preferred drug and is to date the only one used for DEB in the treatment of human coronary arteries [17] . Also, the future impact of using DEBs with drugs other than paclitaxel remains to be investigated [19, 20] .
CONCLUSIONS AND FUTURE PERSPECTIVES
The main indication for the use of DEB in the treatment of de novo coronary lesions seems to be small vessel disease, and especially in patients with high bleeding risk where a shorter time for DAPT treatment is favorable. A DEB-only strategy in bifurcations and in very high-risk patients, e.g., 
